MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Neuroprotective agents"

  • 2017 International Congress

    Neuroactive steroids reverse the dopaminergic neurotransmission defectiveness in chronic hepatic (HE) encephalopathy: a possible involvement in HE related parkinsonism

    O. El Hiba, A. EL Khiat, H. Gamrani (EL Jadida, Morocco)

    Objective: In the present study, we describe the changes of the dopaminergic system occurring in the cirrhotic rats and concomitantly we investigated the effect of…
  • 2017 International Congress

    Relationship between Insulin-like Growth Factor-1 and characteristics of physical activity in patients with Parkinson’s disease

    K. Nagaki, M. Ikenaga, S. Fujioka, Y. Tsuboi (fukuoka, Japan)

    Objective: To clarify the characteristics of decreased physical activity and relationship between physical activity intensity and Insulin-like Growth Factor-1 (IGF-1) in patients with Parkinson's disease…
  • 2017 International Congress

    Deep Brain Stimulation for Parkinson Disease before L-dopa treatment: experience in three cases.

    d. servello, M. Porta, e. zekaj (Milano, Italy)

    Objective:   The goal of these case series is to investigate the possibility of deep brain stimulation (DBS) prior to L-dopa treatment in young Parkinsson…
  • 2017 International Congress

    Predict Cognitive Decline with Clinical Markers in Parkinson’s Disease

    G. Pagano, T. Yousaf,, C. Loane, S. Polychronis, H. Wilson, B. Giordano, F. Niccolini, M. Politis (London, United Kingdom)

    Objective: We investigated which clinical-ready and cost-effective markers are predictive of cognitive impairment (CI) in Parkinson’s disease (PD) in a cohort of 294 patients with…
  • 2017 International Congress

    Off-Target Implications of Nurr1 Agonist Therapy in Parkinson’s disease

    K. Steece-Collier, T. Collier, J. Stancati, C. Kemp, B. Daley, C. Sortwell (Grand Rapids, MI, USA)

    Objective: To examine the impact of Nurr1 agonists on regulation of striatal Nurr1 and levodopa (LD)-induced dyskinesias (LIDs) in a rat model of Parkinson’s disease…
  • 2017 International Congress

    The therapeutic effect of MANF in the MPTP/MPP+-induced model of Parkinson’s disease

    y. liu (shanghai city, China)

    Objective: To observe therapeutic effect of MANF in the attenuation of neurotoxin MPTP/MPP+-induced model of Parkinson's disease Background: Mesencephalic astrocyte-derived neurotrophic factor (MANF) is a…
  • 2017 International Congress

    Synthesis and pharmacological evaluation of 16-aryldieno steroids as anti-parkinsonian agents in LPS induced Neuroinflammation Model of Rat

    R. Bansal, R. Singh (Chandigarh, India)

    Objective: The present study is aimed at design and synthesis of new therapeutically useful steroidal neuroprotective derivatives as anti-parkinsonian agents. The new 16-aryldieno steroidal derivatives…
  • 2017 International Congress

    Cinnamomum verum on Learning and Memory in Wistar Albino Rats

    N. AHMED, D. AGRAWAL, A. CHUGHTAI (ALIGARH, India)

    Objective: Several studies have been performed on Cinnamomum verum,but not much is known about the activity of Cinnamomum verum on Memory Enhancing.Therefore Cinnamomum verum is selected…
  • 2017 International Congress

    Neuroprotective Potency of Tetrahydroisoquinoline a Novel Ayurveda Molecule in Experimental Parkinson’s Disease

    R. Banerjee, D. Nthenge-Ngumbau, R. Singh, P. Jaisankar, K. Mohanakumar, S. Biswas (Kolkata, India)

    Objective: Tetrahydroisoquinoline (TIQ) an identified alkaloid from ancient Indian ‘Ayurveda’ medicine for Parkinson’s disease (PD) was tested for neuroprotection in a cellular system and a…
  • 2017 International Congress

    Multi-modal retention in a phase III clinical trial in early Parkinson disease (STEADY-PD III)

    B. Greco, T. Simuni, J. Denmark, S. Henderson, J. Lowell, S. Sharma, C. Tarolli, D. Young, K. Biglan (Rochester, NY, USA)

    Objective: To evaluate novel retention strategies in an ongoing phase 3 clinical trial in individuals with Parkinson disease (PD) Background: Adequate participant retention is a…
  • « Previous Page
  • 1
  • …
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley